ZA202109124B - Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications - Google Patents
Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applicationsInfo
- Publication number
- ZA202109124B ZA202109124B ZA2021/09124A ZA202109124A ZA202109124B ZA 202109124 B ZA202109124 B ZA 202109124B ZA 2021/09124 A ZA2021/09124 A ZA 2021/09124A ZA 202109124 A ZA202109124 A ZA 202109124A ZA 202109124 B ZA202109124 B ZA 202109124B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical compositions
- therapeutic applications
- compounds targeting
- targeting proteins
- protein
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004853 protein function Effects 0.000 abstract 1
- 230000007111 proteostasis Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852844P | 2019-05-24 | 2019-05-24 | |
| PCT/US2020/034264 WO2020242960A1 (en) | 2019-05-24 | 2020-05-22 | Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202109124B true ZA202109124B (en) | 2023-10-25 |
Family
ID=71092611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/09124A ZA202109124B (en) | 2019-05-24 | 2021-11-16 | Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications |
Country Status (14)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| IL293481A (en) * | 2019-12-06 | 2022-08-01 | Celgene Corp | Processes for the preparation of 2-(4-chlorophenyl)-n-((2-(2,6-dioxypyridin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| AU2020398965A1 (en) * | 2019-12-12 | 2022-06-30 | Biotheryx, Inc. | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications |
| JP7871189B2 (ja) * | 2019-12-17 | 2026-06-08 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN122562781A (zh) * | 2020-10-07 | 2026-08-14 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| TW202231269A (zh) | 2020-10-23 | 2022-08-16 | 美商拜歐斯瑞克斯公司 | Kras蛋白降解劑、其醫藥組合物及其治療應用 |
| US20240124418A1 (en) | 2020-12-14 | 2024-04-18 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| EP4320125A1 (en) * | 2021-04-05 | 2024-02-14 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
| AU2022289605B2 (en) * | 2021-06-08 | 2024-12-19 | Hangzhou Glubio Pharmaceutical Co., Ltd. | Isoindolinone compounds, and uses thereof |
| CN117440948A (zh) * | 2021-06-28 | 2024-01-23 | 成都分迪药业有限公司 | 酰胺类化合物及其用途 |
| WO2023001028A1 (zh) * | 2021-07-19 | 2023-01-26 | 南京明德新药研发有限公司 | 杂芳-3-哌啶二酮类化合物及其应用 |
| WO2023069708A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and uses thereof |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| WO2023070120A1 (en) * | 2021-10-22 | 2023-04-27 | Biotheryx, Inc. | Ketoamides for treating malignancy |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) * | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| US12662467B2 (en) | 2022-04-18 | 2026-06-23 | BioThery X, Inc. | Isoindolinones, pharmaceutical compositions, and therapeutic applications |
| CN114835680A (zh) * | 2022-04-29 | 2022-08-02 | 成都分迪药业有限公司 | 卤素取代异吲哚啉化合物及其应用 |
| JP2025522795A (ja) * | 2022-06-27 | 2025-07-17 | ピン セラピューティクス、インコーポレイテッド | カゼインキナーゼ１アルファを分解するための化合物及び方法 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| JP2025531869A (ja) * | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024167423A1 (en) * | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| WO2024222918A1 (zh) * | 2023-04-28 | 2024-10-31 | 中国药科大学 | 一种苯并六元杂环类gspt1蛋白降解剂及其应用 |
| WO2025067255A1 (zh) * | 2023-09-26 | 2025-04-03 | 映恩生物制药（苏州）有限公司 | 哌啶二酮类化合物、其制备方法和用途 |
| WO2026098548A1 (zh) * | 2024-11-07 | 2026-05-15 | 四川科伦博泰生物医药股份有限公司 | 蛋白降解剂、其药物组合物及其用途和方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| JP5469604B2 (ja) * | 2007-09-19 | 2014-04-16 | ４エスツェー アクチェンゲゼルシャフト | 新規テトラヒドロ融合ピリジン |
| TWI782395B (zh) * | 2016-01-08 | 2022-11-01 | 美商西建公司 | 抗增生化合物，及其醫藥組合物及用途 |
| WO2017201069A1 (en) * | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| KR101825065B1 (ko) * | 2016-05-24 | 2018-02-05 | 한국화학연구원 | Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN108069959A (zh) * | 2016-11-10 | 2018-05-25 | 凯惠科技发展(上海)有限公司 | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 |
| JP2020504711A (ja) * | 2016-12-21 | 2020-02-13 | バイオセリックス， インコーポレイテッド | タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用 |
| WO2018169777A1 (en) | 2017-03-14 | 2018-09-20 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| CN108929307A (zh) * | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 |
| SG11202104495YA (en) * | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| US10905684B2 (en) | 2018-06-13 | 2021-02-02 | Biotheryx, Inc. | Aminoamide compounds |
| WO2020023782A1 (en) * | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
-
2020
- 2020-05-22 CN CN202080052899.5A patent/CN114502543A/zh active Pending
- 2020-05-22 JP JP2021569449A patent/JP2022533260A/ja active Pending
- 2020-05-22 SG SG11202112355VA patent/SG11202112355VA/en unknown
- 2020-05-22 EA EA202192910A patent/EA202192910A1/ru unknown
- 2020-05-22 WO PCT/US2020/034264 patent/WO2020242960A1/en not_active Ceased
- 2020-05-22 EP EP20732707.3A patent/EP3976623A1/en not_active Withdrawn
- 2020-05-22 TW TW109117256A patent/TW202110818A/zh unknown
- 2020-05-22 MX MX2021014345A patent/MX2021014345A/es unknown
- 2020-05-22 KR KR1020217039259A patent/KR20220023343A/ko not_active Withdrawn
- 2020-05-22 AU AU2020283744A patent/AU2020283744A1/en not_active Abandoned
- 2020-05-22 CA CA3140078A patent/CA3140078C/en active Active
- 2020-05-26 US US16/882,750 patent/US11345712B2/en active Active
-
2021
- 2021-11-16 ZA ZA2021/09124A patent/ZA202109124B/en unknown
- 2021-11-17 IL IL288204A patent/IL288204A/en unknown
-
2022
- 2022-05-30 US US17/804,566 patent/US20220298172A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220298172A1 (en) | 2022-09-22 |
| MX2021014345A (es) | 2022-01-06 |
| KR20220023343A (ko) | 2022-03-02 |
| US20200369679A1 (en) | 2020-11-26 |
| CA3140078A1 (en) | 2020-12-03 |
| WO2020242960A1 (en) | 2020-12-03 |
| JP2022533260A (ja) | 2022-07-21 |
| CA3140078C (en) | 2023-11-28 |
| EP3976623A1 (en) | 2022-04-06 |
| CN114502543A (zh) | 2022-05-13 |
| IL288204A (en) | 2022-01-01 |
| TW202110818A (zh) | 2021-03-16 |
| AU2020283744A1 (en) | 2021-12-09 |
| SG11202112355VA (en) | 2021-12-30 |
| EA202192910A1 (ru) | 2022-03-18 |
| US11345712B2 (en) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014345A (es) | Compuestos dirigidos a proteinas y composiciones farmaceuticas de los mismos, y sus aplicaciones terapeuticas. | |
| WO2021107656A3 (ko) | 신규한 퀘르세틴 리독스 유도체 및 bet 억제제로서의 용도 | |
| PH12021500014A1 (en) | Fused ring compounds | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| CY1123260T1 (el) | Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου | |
| EP4483881A3 (en) | Fused ring compounds | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| MY191030A (en) | Gdf15 fusion proteins and uses thereof | |
| ZA202306296B (en) | Novel quinazoline derivative compound as sos1 inhibitor, and use thereof | |
| MX2018015353A (es) | Usos terapeuticos de un inhibidor de c-raf. | |
| EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
| BR112021023024A2 (pt) | Anticorpo contra claudina 18a2 e uso do mesmo | |
| JOP20220002B1 (ar) | عمليات ومركب وسيط لتحضير واسع النطاق لـ 2، 4، 6-تراي فلورو-n-[6-(1-ميثيل-بيبريدين-4-كاربونيل)-بيريدين-2-يل]-بنزاميد هيمي سكسينات، وتحضير 2، 4، 6-تراي فلورو-n-[6-(1-ميثيل-بيبريدين-4-كاربونيل)-بيريدين-2-يل]-بنزاميد أسيتات | |
| EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| BR112021018608A2 (pt) | Anticorpos para claudina-6 e conjugados de fármaco | |
| WO2018189661A3 (en) | Methods and compounds for treating diabetes | |
| AU2016210835A8 (en) | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders | |
| WO2020022898A3 (en) | Off-the-shelf cancer vaccines | |
| MA53765B2 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| MX2019006630A (es) | Estructura cristalina de gremlina 1 y anticuerpo inhibidor. | |
| EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
| WO2020127376A3 (en) | Polypeptides | |
| WO2020047326A3 (en) | Decoy polypeptides |